Top Markets
#1 MowCat MowCat +49.06%
#2 Velvet Velvet +37.57%
#3 Derive Derive +19.79%
#4 Audiera Audiera +18.76%
#5 Quack AI Quack AI +18.38%
#6 Bermuda Shorts Bermuda Shorts +15.44%
#7 aPriori aPriori +14.44%
#8 Biconomy Biconomy +14.37%
#9 Cross Cross +12.38%
#10 MarsCoin MarsCoin +12.30%
Coin of the day
MowCat MowCat
설정
언어
한국어
통화
USD
테마
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
주식 순위 #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
주가
$1.85
마지막 동기화: 2024-08-19
시가총액
$3.96M
변동 (1일)
2.78%
변동 (1년)
0.00%
국가
US
거래 MyMD Pharmaceuticals, Inc. (MYMD)

카테고리

Healthcare
MyMD Pharmaceuticals, Inc. (MYMD)의 매출
Aug 2026 기준 매출 TTM: 0
MyMD Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
MyMD Pharmaceuticals, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE